Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis.

Ginenus FekaduJiaqi YaoJoyce Hoi-Sze You

Published in: PloS one (2022)

The BDQ-based therapy appeared to be cost-effective and showed a high probability to be accepted as the preferred cost-effective option for active XDR-TB treatment.

Keyphrases

drug resistant
multidrug resistant
acinetobacter baumannii
south africa
mycobacterium tuberculosis
emergency department
cystic fibrosis
pseudomonas aeruginosa
hepatitis c virus
mesenchymal stem cells
cell therapy